

## Strong Q1 beat on all fronts but upside capped...

**About the stock:** Sun Pharma is the world's fourth largest specialty generic company with sales of US\$3.8 billion & boasts of 43 manufacturing sites addressing segments like specialty products, branded generics, complex generics, pure generics and APIs.

- With a market share of 8.2%, Sun is ranked No. 1 in domestic formulations. It enjoys leadership position in 11 specialties based on prescription
- Revenue breakup: US formulations~30%, Indian branded~30%, Emerging markets~17%, RoW~14%, API & others~6%

**Q1FY22 Results:** Sun Pharma reported robust Q1FY22 results.

- Sales were up 28.1% YoY to ₹ 9718.7 crore
- EBITDA in Q1FY22 was at ₹ 2821 crore, up 53% YoY with margins at 29%
- Consequent adjusted PAT was at ₹ 2075 crore (up 81% YoY)

**What should investors do?** Sun Pharma's share price has declined by ~0.8x over the past five years (from ~₹ 763 in June 2016 to ~₹ 675 levels in June 2021).

- We maintain HOLD as we wait for more consistency on the specialty front. At the current level, the stock has priced in the medium term traction

**Target Price and Valuation:** We value Sun at ₹ 800 i.e. 28x P/E on FY23E EPS

**Key triggers for future price performance:**

- It has embarked on a strategy to in-license latest generation patent protected products from various innovators
- Higher contribution from specialty & strong domestic franchise is likely to change the product mix towards more remunerative businesses by FY23
- In the US, Sun diversifying into specialty products like Ilumya, Levulan, BromSite, Cequa, Xelpros, Odomzo, Yonsa, winlwi etc.

**Alternate Stock Idea:** Apart from Sun, in our healthcare coverage we also like Cipla.

- It has a diversified portfolio with respiratory segment leadership
- BUY with a target price of ₹ 1040

### Key Financial Summary

Key Financials (₹ Crore)	FY19	FY20	FY21	5 year CAGR (FY16-21)	FY22E	FY23E	2 year CAGR (FY21-23E)
Net Sales	29028.1	32837.5	33498.1	3.2	37801.4	40499.6	10.0
EBITDA	6269.8	6989.8	8491.4	-0.5	9066.4	9719.9	7.0
EBITDA Margins (%)	21.6	21.3	25.3		24.0	24.0	
Adj. Profit	3803.3	4025.6	7210.0	5.0	6030.8	6858.1	-2.5
Adj. EPS (₹)	15.9	16.8	30.0		25.1	28.6	
PE (x)	71.7	49.3	64.0		44.9	27.1	
EV to EBITDA (x)	29.5	26.1	21.1		19.7	17.9	
RoE (%)	9.2	8.9	15.5		12.0	12.2	
RoCE (%)	10.3	10.0	14.4		15.1	15.3	

Source: Company, ICICI Direct Research




### Particulars

Particular	Amount
Market Capitalisation	₹ 185709 crore
Debt (FY21)	₹ 3343 crore
Cash & Equivalents (FY21)	₹ 6446 crore
EV (₹ Cr)	₹ 182606 crore
52 week H/L (₹)	780/453
Equity capital	₹ 239.9 crore
Face value	₹ 1

### Shareholding pattern

(in %)	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21
Promoter	54.7	54.7	54.5	54.5	54.5
Others	45.3	45.3	45.5	45.5	45.5

### Price Chart



### Recent Event & Key risks

- In-license of Winlevi in US & Canada adds to derma portfolio
- **Key Risk:** (i) Price erosion impact (ii) Better traction for specialty products

### Research Analyst

Siddhant Khandekar  
siddhant.khandekar@icicisecurities.com  
Mitesh Shah  
mitesh.shah@icicisecurities.com

## Key takeaways of recent quarter & conference call highlights

### Q1FY22 Results: Robust performance continues

- Revenues grew 28.1% YoY to ₹ 9718.7 crore. Indian formulations grew 38.5% YoY to ₹ 3308.4 crore. US formulations grew to ₹ 2800 crore, up 31.1% YoY. Emerging markets business grew 22% YoY to ₹ 1605.3 crore while RoW Markets business grew 32.8% YoY to ₹ 1368 crore. API segment de-grew 1.4% YoY to ₹ 587.8 crore
- EBITDA margins expanded 472 bps YoY to 29.0% mainly due steady employee expense. Subsequently, EBITDA grew 53% YoY to ₹ 2821.1 crore. Adjusting for exceptional items in current and base quarter, PAT grew 81.1% YoY to ₹ 2075.1 crore
- While the company's US generics front is going through calibrated product rationalisation, the specialty segment looks promising due to robust product pipeline, steady progress. This metamorphic shift from generics to specialty, however, is likely to weigh on US growth in the near term. That said, higher contribution from specialty and strong domestic franchise is likely to change the product mix towards more remunerative businesses by FY22. This would have positive implications for margins also as we expect faster absorption of frontloaded costs on the specialty front

### Q1FY22 Earnings Conference Call highlights

- Results were driven by robust core business growth, low base and some sale of Covid products
- India contributed 34% of total revenue. Covid products contributed 8-10% of India sales
- The company launched 13 new products in the Indian market in Q1FY22
- US was 29% of total sales at US\$380 million, driven by growth in specialty business
- The management witnessed an uptick in sales of ILumya, Cequa, etc, which countered the loss in business of Absorica
- Following specialty products are under development-
  - ILumya for Psoriatic Arthritis
  - GLP 1R for diabetes
  - SCD-044 for Atopic Dermatitis
- Recently licensed Winlevi (topical treatment for acne) will add to Derma portfolio and the management expects to launch the same in the US by December 2021
- Patients doctor visit in the US is still below pre Covid levels but the situation is getting normalised
- Global specialty revenue for Q1FY22: US\$148 million. The management guided for double digit growth in specialty portfolio for FY22
- Consolidated R&D investment for Q1FY22 was ₹ 592.6 crore compared to ₹ 420.6 million for Q1 last year. Specialty R&D was 26% of total R&D investment
- Approved ANDAs: 505, approved NDAs: 53 filings: 86 ANDAs & 13 NDAs await US FDA approval, including 22 tentative approvals. Six approvals were received in Q1FY22
- The company has repaid debt of about US\$185 million in Q1FY22. Over the last five quarters, debt repaid was about US\$765 million. The company is net cash positive (ex-Taro)

**Exhibit 1: Variance Analysis**

	Q1FY22	Q1FY22E	Q1FY21	YoY (%)	Q4FY21	QoQ (%)	Comments
Revenue	9,718.7	9,063.2	7,585.3	28.1	8,523.0	14.0	YoY growth mainly due robust core business growth, low base and some sale of Covid products. Beat vis-à-vis I-direct estimates mainly due to higher-than-expected domestic and US sepciality sales
Raw Material Expens	2,649.4	2,401.7	1,969.6	34.5	2,240.8	18.2	
Gross margins (%)	72.7	73.5	74.0	-129 bps	73.7	-97 bps	
Employee Expenses	1,758.7	1,783.8	1,759.0	0.0	1,677.5	4.8	
Other Expenditure	2,489.5	2,673.6	2,013.1	23.7	2,556.3	-2.6	
Total Expenditure	6,897.7	6,859.2	5,741.7	20.1	6,474.5	6.5	
EBITDA	2,821.1	2,204.0	1,843.5	53.0	2,048.5	37.7	
EBITDA (%)	29.0	24.3	24.3	472 bps	24.0	499 bps	YoY improment mainly due to operational leverage and lower traveling cost in India
Interest	35.1	24.8	52.0	-32.5	30.1	16.6	
Depreciation	503.2	546.0	495.9	1.5	553.5	-9.1	
Other income	152.5	179.3	153.8	-0.8	111.0	37.4	
EO	631.1	0.0	3,633.3		672.8		
PBT	1,804.2	1,812.6	-2,183.9	LP	903.0	99.8	
Tax	395.6	344.4	245.9	60.9	55.0	618.7	
MI	-40.1	-25.3	-770.6	NA	-51.7	NA	
Net Profit	1,444.2	1,487.9	-1,655.6	LP	894.2	61.5	
Adj. Net Profit	1,979.2	1,487.9	1,146.0	72.7	1,343.1	47.4	YoY growth mainly due to strong operational performance and lower interest cost

**Key Metrics**

India formulations	3,308.4	2,866.1	2,388.4	38.5	2,670.9	23.9	Besides strong growth in chronic segment and recovery in semi chronic segment, the company's Q1 growth was also driven by sale of Covid products
US formulations	2,800.0	2,696.5	2,136.4	31.1	2,694.6	3.9	YoY growth amid low base and strong growth in speciality segment
Emerging Markets	1,605.3	1,579.3	1,316.1	22.0	1,401.5	14.5	YoY growth in US\$ term was 25%
RoW	1,368.0	1,287.5	1,030.0	32.8	1,191.3	14.8	YoY growth in US\$ term was 35%
APIs	587.8	536.7	596.3	-1.4	473.1	24.2	
US Sales (Ex Taro)	1,714.7	1,611.3	1,244.0	37.8	1,613.1	6.3	

Source: Company, ICICI Direct Research

**Exhibit 2: Change in estimates**

	FY22E			FY23E			
(₹ Crore)	Old	New	% Change	Old	New	% Change	
Total Operating Income	36,836.2	37,801.4	2.6	40,167.5	40,499.6	0.8	
EBITDA	8,381.3	9,066.4	8.2	9,439.4	9,719.9	3.0	
EBITDA Margin (%)	22.8	24.0	118 bps	23.5	24.0	50 bps	Lower than expected decline in margins in accretive speciality segment
Adjusted PAT	5,629.1	6,030.8	7.1	6,703.8	6,858.1	2.3	
EPS (Adjusted)	23.5	25.1	6.9	27.9	28.6	2.4	

Source: ICICI Direct Research

**Exhibit 3: Assumptions**

	Current				Earlier		Comments
₹ crore	FY20	FY21	FY22E	FY23E	FY22E	FY23E	
Indian Formulations	9,710.5	10,343.2	12,369.6	13,456.9	11,879.6	13,305.1	
US Formulations	10,542.5	10,083.9	11,007.9	11,519.6	10,425.6	10,991.5	Better-than-expected sales guidance of speciality segment
RoW markets	10,025.3	10,602.5	12,055.4	13,032.0	11,948.8	13,143.7	
APIs	2,047.0	2,109.6	2,176.8	2,285.6	2,187.4	2,296.8	

Source: ICICI Direct Research

**Exhibit 4: Financial Summary**

	Revenues	Growth	EPS	Growth	P/E	EV/EBITDA	RoE	RoCE
	(₹ crore)	(%)	(₹)	(%)	(x)	(X)	(%)	(%)
FY20	32838	13.1	16.8	5.8	49.3	26.1	8.9	10.0
FY21	33498	2.0	30.0	79.1	64.0	21.1	15.5	14.4
FY22E	37801	12.8	25.1	-16.4	44.9	19.7	12.0	15.1
FY23E	40500	7.1	28.6	13.7	27.1	17.9	12.2	15.3

Source: ICICI Direct Research

**Exhibit 5: Revenue break-up**

₹ crore	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E	FY16-21 (%)	FY21-23E (%)
Domestic	7,299.2	7,749.1	8,029.3	7,348.3	9,710.5	10,343.2	12,369.6	13,456.9	7.2	14.1
US	13,516.9	13,758.8	8,746.6	10,673.6	10,542.5	10,083.9	11,007.9	11,519.6	-5.7	6.9
Emerging Markets	3,584.3	4,544.8	4,839.2	5,359.0	5,504.4	5,783.4	6,519.4	7,010.8	10.0	10.1
ROW	2,161.8	2,583.2	2,974.0	3,452.6	4,521.0	4,819.1	5,536.0	6,021.2	17.4	11.8
API & Others	1,475.2	1,634.5	1,476.8	1,811.7	2,047.0	2,109.6	2,176.8	2,285.6	7.4	4.1
ROW	5,746.1	7,128.0	7,813.2	8,811.7	10,025.3	10,602.5	12,055.4	13,032.0	13.0	10.9


Source: ICICI Direct Research

**Exhibit 6: Trends in quarterly performance**

(₹ Crore)	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22	YoY (%)	QoQ (%)
Total Operating Income	7224.2	6937.6	7740.2	7163.9	8374.4	8123.4	8154.9	8184.9	7585.3	8553.1	8836.8	8523.0	9718.7	28.1	14.0
Raw Material Expenses	2106.8	1757.7	2165.7	1838.8	2457.8	2267.9	2200.0	2304.8	1969.6	2146.3	2333.4	2240.8	2649.4	34.5	18.2
Gross Profit Margin (%)	70.8	74.7	72.0	74.3	70.7	72.1	73.0	71.8	74.0	74.9	73.6	73.7	72.7		
Employee Expenses	1433.0	1470.3	1495.0	1568.8	1540.4	1620.9	1549.1	1651.9	1759.0	1705.3	1720.5	1677.5	1758.7	0.0	4.8
% of Revenue	19.8	21.2	19.3	21.9	18.4	20.0	19.0	20.2	23.2	19.9	19.5	19.7	18.1		
Other Expenditure	2077.6	2178.4	1926.7	2739.6	2380.6	2444.8	2564.3	2865.2	2013.1	2508.2	2376.8	2556.3	2489.5	23.7	-2.6
% of Revenue	28.8	31.4	24.9	38.2	28.4	30.1	31.4	35.0	26.5	29.3	26.9	30.0	25.6		
Total Expenditure	5617.5	5406.4	5587.3	6147.1	6378.8	6333.6	6313.5	6821.9	5741.7	6359.9	6430.6	6474.5	6897.7	20.1	6.5
% of Revenue	77.8	77.9	72.2	85.8	76.2	78.0	77.4	83.3	75.7	74.4	72.8	76.0	71.0		
EBITDA	1606.7	1531.2	2152.9	1016.8	1995.6	1789.7	1841.4	1363.0	1843.5	2193.3	2406.1	2048.5	2821.1	53.0	37.7
EBITDA Margin (%)	22.2	22.1	27.8	14.2	23.8	22.0	22.6	16.7	24.3	25.6	27.2	24.0	29.0		
Depreciation	401.6	426.5	471.1	454.1	457.1	473.3	547.0	575.4	495.9	498.6	531.9	553.5	503.2	1.5	-9.1
Other Income	199.8	351.2	193.1	281.5	213.0	200.9	119.9	102.2	153.8	255.8	315.0	111.0	152.5	-0.8	37.4
PBIT	1404.8	1455.9	1874.9	844.3	1751.5	1517.3	1414.3	889.9	1501.4	1950.5	2189.2	1606.0	2470.4	64.5	53.8
Interest	130.9	129.5	144.8	150.0	104.1	83.9	63.0	51.8	52.0	33.3	26.1	30.1	35.1	-32.5	16.6
Less: Exceptional Items	0.0	1214.4	0.0	0.0	0.0	0.0	0.0	260.6	3633.3	0.0	0.0	672.8	631.1		
PBT	1273.9	111.9	1730.1	694.2	1647.4	1433.4	1351.3	577.4	-2183.9	1917.2	2163.1	903.0	1804.2	-182.6	99.8
Total Tax	163.9	218.9	270.9	-28.8	146.1	266.0	327.6	83.1	245.9	-31.2	244.9	55.0	395.6	60.9	618.7
PAT before MI	1110.1	-107.0	1459.2	723.1	1501.4	1167.4	1023.7	494.3	-2429.8	1948.4	1918.1	848.0	1408.7	-158.0	66.1
Minority Interest	122.7	110.0	219.2	105.2	109.2	99.1	105.9	92.9	-770.6	130.0	60.9	-51.7	-40.1	-94.8	-22.4
PAT after MI	987.3	-217.0	1240.0	617.8	1392.2	1068.3	917.9	401.4	-1659.2	1818.4	1857.2	899.7	1448.8	-187.3	61.0
Profit from Associates	1.0	-1.9	1.8	-2.4	-4.7	-4.2	-4.3	-1.6	3.6	-5.6	-4.7	-5.6	-4.6		
PAT	988.3	-218.8	1241.9	615.4	1387.5	1064.1	913.5	399.8	-1655.6	1812.8	1852.5	894.2	1444.2	-187.2	61.5
Adjusted PAT	988.3	995.6	1241.9	615.4	1387.5	1064.1	913.5	660.5	1146.0	1812.8	1852.5	1343.1	1979.2	72.7	47.4
Adjusted EPS (₹)	4.1	4.1	5.2	2.6	5.8	4.4	3.8	2.8	4.8	7.6	7.7	5.6	8.2		


Source: ICICI Direct Research

**Exhibit 7: Revenues to grow at CAGR of 10% over FY21-23E**




Source: ICICI Direct Research, Company

**Exhibit 8: US to grow at CAGR of ~6.9% over FY21-23E**




Source: ICICI Direct Research, Company

**Exhibit 9: Domestic to grow at 14.1% CAGR in FY21-23E**




Source: ICICI Direct Research, Company

**Exhibit 10: EBITDA & EBITDA margins trend**




Source: ICICI Direct Research, Company

**Exhibit 11: PAT & PAT margins trend**



Source: ICICI Direct Research, Company

**Exhibit 12: RoCE & RoE trend**



Source: ICICI Direct Research, Company

## Financial Summary

Exhibit 13: Profit and loss statement ₹ crore				
(Year-end March)	FY20	FY21	FY22E	FY23E
<b>Revenues</b>	<b>32,837.5</b>	<b>33,498.1</b>	<b>37,801.4</b>	<b>40,499.6</b>
Growth (%)	13.1	2.0	12.8	7.1
Raw Material Expenses	9,230.5	8,690.1	10,305.1	10,529.9
Employee Expenses	6,362.4	6,862.2	7,515.7	8,302.4
Other Expenditure	10,254.9	9,454.5	10,914.3	11,947.4
Total Operating Expenditure	25,847.7	25,006.8	28,735.1	30,779.7
<b>EBITDA</b>	<b>6,989.8</b>	<b>8,491.4</b>	<b>9,066.4</b>	<b>9,719.9</b>
Growth (%)	11.5	21.5	6.8	7.2
Depreciation	2,052.8	2,080.0	2,012.9	2,108.7
Interest	302.7	141.4	140.4	80.5
Other Income	636.0	835.5	990.7	1,309.6
PBT	5,270.2	7,105.5	7,903.9	8,840.3
Less: Exceptional Items	260.6	4,306.1	2,374.6	0.0
Total Tax	822.8	514.7	1,212.3	1,679.7
PAT before MI	4,186.8	2,284.7	4,317.0	7,160.7
Minority Interest	407.0	-631.5	164.0	284.1
PAT	3,764.9	2,903.8	4,134.5	6,858.1
<b>Adjusted PAT</b>	<b>4,025.6</b>	<b>7,210.0</b>	<b>6,030.8</b>	<b>6,858.1</b>
Growth (%)	5.8	79.1	-16.4	13.7
<b>EPS (Adjusted)</b>	<b>16.8</b>	<b>30.0</b>	<b>25.1</b>	<b>28.6</b>

Source: Company, ICICI Direct Research

Exhibit 14: Cash flow statement ₹ crore				
(Year-end March)	FY20	FY21	FY22E	FY23E
Profit/(Loss) after taxation	3663.7	1796.4	4134.5	6858.1
Depreciation	2052.8	2080.0	2012.9	2108.7
(Inc)/Dec in Current Assets	-292.5	-869.9	-3411.4	-1728.8
(Inc)/Dec in Current Liabilities	1191.0	3434.0	1991.8	1128.6
Others	-60.2	-270.1	140.4	80.5
<b>CF from operation Activities</b>	<b>6554.8</b>	<b>6170.4</b>	<b>4868.1</b>	<b>8447.2</b>
Purchase of Fixed Assets	-1450.0	-1073.0	-1478.9	-1480.0
(Inc)/Dec in Investments	-1551.8	1167.1	-2305.4	-2305.4
Others	1374.1	-326.0	-312.4	-225.7
<b>CF from Investing Activities</b>	<b>-1627.7</b>	<b>-231.9</b>	<b>-4096.7</b>	<b>-4011.1</b>
Inc / (Dec) in Loan Funds	-3341.9	-4489.6	-1000.0	-1000.0
Inc / (Dec) in Equity Capital	-425.0	-185.4	0.0	0.0
Dividend and dividend tax	-1662.6	-1586.2	-413.5	-685.8
Other Financial Activities	-285.6	280.8	-140.4	-80.5
<b>CF from Financing Activities</b>	<b>-5715.1</b>	<b>-5980.5</b>	<b>-1553.8</b>	<b>-1766.3</b>
Cash generation during the year	-788.1	-42.0	-782.4	2669.8
Op bal Cash & Cash equivalents	7275.6	6487.6	6445.5	5663.2
<b>Closing Cash/ Cash Equivalent</b>	<b>6487.6</b>	<b>6445.5</b>	<b>5663.2</b>	<b>8332.9</b>
<b>Free Cash Flow</b>	<b>5104.8</b>	<b>5097.3</b>	<b>3389.3</b>	<b>6967.2</b>

Source: Company, ICICI Direct Research

Exhibit 15: Balance Sheet ₹ crore				
(Year-end March)	FY20	FY21	FY22E	FY23E
Equity Capital	239.9	239.9	239.9	239.9
Reserve and Surplus	45,024.5	46,222.9	49,943.9	56,116.3
Total Shareholders funds	45,264.5	46,462.8	50,183.9	56,356.2
Total Debt	8,314.9	3,343.0	2,343.0	1,343.0
Deferred Tax Liability	58.1	44.5	47.6	51.0
Minority Interest	3,860.2	3,017.1	3,181.1	3,465.2
Other LT Liabilities & LT Provision	1,334.3	1,098.6	1,175.5	1,257.8
<b>Total Liabilities</b>	<b>58,832.0</b>	<b>53,966.0</b>	<b>56,931.1</b>	<b>62,473.2</b>
Gross Block - Fixed Assets	28,634.5	29,614.4	31,093.2	32,573.2
Accumulated Depreciation	12,269.1	14,349.0	16,361.9	18,470.6
Net Block	16,365.5	15,265.3	14,731.3	14,102.6
Capital WIP	1,220.3	1,566.8	1,566.8	1,566.8
Total Fixed Assets	17,585.8	16,832.2	16,298.1	15,669.5
Investments	10,143.1	9,612.5	11,917.9	14,223.3
Deferred tax assets	3,175.3	3,556.4	3,805.4	4,071.8
Goodwill on Consolidation	6,481.5	6,287.6	6,287.6	6,287.6
LT Loans & Advances & Assets	4,110.0	4,066.0	4,350.6	4,655.2
Cash	6,487.6	6,445.5	5,663.2	8,332.9
Debtors	9,421.2	9,061.4	11,269.8	12,074.2
Loans and Advances	148.4	56.0	59.9	64.1
Inventory	7,875.0	8,997.0	10,003.5	10,717.5
Other current assets	2,824.6	2,752.1	2,944.7	3,150.9
Total Current Assets	26,756.8	27,312.0	29,941.1	34,339.6
Creditors	4,093.7	3,973.7	5,261.7	5,637.2
Provisions & other current liability	5,326.7	972.7	10,408.0	11,136.5
Total Current Liabilities	9,420.5	13,700.7	15,669.6	16,773.7
Net Current Assets	17,336.3	13,611.3	14,271.5	17,565.9
<b>Application of Funds</b>	<b>58,832.0</b>	<b>53,966.0</b>	<b>56,931.1</b>	<b>62,473.2</b>

Source: Company, ICICI Direct Research

Exhibit 16: Key ratios				
(Year-end March)	FY20	FY21	FY22E	FY23E
<b>Per share data (₹)</b>				
Adjusted EPS	16.8	30.0	25.1	28.6
BV per share	188.7	193.6	209.2	234.9
Dividend per share	1.0	7.5	1.7	2.9
Cash Per Share	27.0	26.9	23.6	34.7
<b>Operating Ratios (%)</b>				
Gross Margin	71.9	74.1	72.7	74.0
EBITDA Margin	21.3	25.3	24.0	24.0
PAT Margin	12.3	21.5	16.0	16.9
Inventory days	87.5	98.0	96.6	96.6
Debtor days	104.7	98.7	108.8	108.8
Creditor days	45.5	43.3	50.8	50.8
Asset Turnover	0.6	0.7	0.7	0.7
EBITDA Conversion rate	93.8	72.7	53.7	86.9
<b>Return Ratios (%)</b>				
RoE	8.9	15.5	12.0	12.2
RoCE	10.0	14.4	15.1	15.3
RoIC	11.5	16.3	16.9	17.5
<b>Valuation Ratios (x)</b>				
P/E	49.3	64.0	44.9	27.1
EV / EBITDA	26.1	21.1	19.7	17.9
EV / Net Sales	5.6	5.4	4.7	4.3
Market Cap / Sales	5.7	5.5	4.9	4.6
Price to Book Value	4.1	4.0	3.7	3.3
<b>Solvency Ratios</b>				
Debt / EBITDA	1.2	0.4	0.3	0.1
Debt / Equity	0.2	0.1	0.0	0.0
Current Ratio	2.2	1.5	1.5	1.6
Working Capital Cycle	146.8	153.5	154.6	154.6

Source: Company, ICICI Direct Research

## RATING RATIONALE

ICICI Direct endeavors to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

[pankaj.pandey@icicisecurities.com](mailto:pankaj.pandey@icicisecurities.com)

ICICI Direct Research Desk,  
ICICI Securities Limited,  
1st Floor, Akruti Trade Centre,  
Road No 7, MIDC,  
Andheri (East)  
Mumbai – 400 093  
[research@icicidirect.com](mailto:research@icicidirect.com)



## ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter CA, Mitesh Shah, (cleared all 3 levels of CFA), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

## Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on [www.icicibank.com](http://www.icicibank.com).

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc. as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit [icicidirect.com](http://icicidirect.com) to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.